At variance, PKCη defective CD8+ T cells have not been reported to impact either tumor growth or the frequency and functionality of CD8+ effector T cells [287], proving that the acquisition of a more inflamed TME can be achieved by indirectly targeting intra-tumor Treg PKCη. This evidence concerns the gene CD8A and neoplasm.